Zymeworks Inc (ZYME)

Currency in USD
25.84
-0.61(-2.31%)
Closed·
25.840.00(0.00%)
·
Advertisement
ZYME is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
25.5326.52
52 wk Range
21.5231.97
Key Statistics
Prev. Close
25.84
Open
26.45
Day's Range
25.53-26.52
52 wk Range
21.52-31.97
Volume
569.93K
Average Volume (3m)
1.07M
1-Year Change
12.3967%
Book Value / Share
3.64
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ZYME Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
43.29
Upside
+67.51%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year

Zymeworks Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

14 Buy
0 Hold
0 Sell
Ratings:
14 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 43.29
(+67.51% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Citizens
Buy39.00+50.93%32.00Maintain13/11/2026
Citi
Buy44.00+70.28%39.00Maintain11/11/2026
TD Cowen
Buy39.00+50.93%34.00Maintain10/11/2026
H.C. Wainwright
Buy56.00+116.72%55.00Maintain10/11/2026
Truist Securities
Buy36.00+39.32%35.00Maintain10/11/2026

Zymeworks Inc Earnings Call Summary for Q1/2026

  • Q1 2026 revenue plunged 91.1% YoY to $2.4M due to absence of non-recurring clinical milestones from prior year
  • Net loss surged 95.6% to $44.2M, though operating expenses declined 6.1% to $49.5M reflecting cost management efforts
  • Cash position strengthened 49.2% to $403.8M with runway extending beyond 2028; $440M in potential milestones anticipated
  • Company advancing Zanidatamab and pan-RAS ADC platform, awaiting regulatory approvals for global commercial launches
  • Stock traded at $23.99 with 0.42% premarket gain; faces execution risks and dependence on milestone payments for cash flow
Last Updated: 11/05/2026, 20:14
Read Full Transcript

Earnings

Latest Release
09/11/2026
EPS / Forecast
2.28 / 2.36
Revenue / Forecast
256.46M / 227.39M
EPS Revisions
Last 90 days

Compare ZYME to Peers and Sector

Metrics to compare
ZYME
Peers
Sector
Relationship
P/E Ratio
41.2x−4.5x−0.2x
PEG Ratio
0.250.010.00
Price/Book
6.9x2.1x2.6x
Price / LTM Sales
6.7x9.5x2.7x
Upside (Analyst Target)
67.5%104.7%68.5%
Fair Value Upside
Unlock7.8%11.5%Unlock

Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company’s platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidates include Ziihera (zanidatamab-hrii), a bispecific antibody targeting HER2-expressing tumors; zanidatamab for the treatment of neoadjuvant populations, breast cancer, and other HER2-expressing cancers; Pasritamig, a bispecific T cell engager targeting human kallikrein 2 for the treatment monotherapy and castration resistant prostate cancer; ZW191, a clinical- antibody-drug conjugates (ADC) that targets folate receptor alpha expressing tumors, including ovarian, endometrial, and non-small cell lung cancers; ZW251, a clinical-stage ADC molecule for the treatment of glypican 3 expressing hepatocellular carcinoma; ZW220, an ADC that targets NaPi2b-expressing NSCLC and ovarian cancer; ZW209, a novel TriTCE targeting Delta-like ligand 3 -expressing tumor cells for the treatment of solid tumors; and ZW1528, a bispecific molecule to treat chronic obstructive pulmonary disease. It has strategic partnerships and collaborations with Jazz Pharmaceuticals plc; Bristol- Myers Squibb company; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Merck Sharp & Dohme Research GmbH; and Janssen Biotech, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
14.32M20.74%378.71M
Other Institutional Investors
85.37M79.26%2.26B
Public Companies & Retail Investors
0.000.00%0.00
Total
99.69M100.00%2.64B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
EcoR1 Capital, LLC33.28%22,970,388607,567
EcoR1 Capital Fund Qualified, L.P.31.27%21,582,563570,859

People Also Watch

22.11
TNGX
-8.52%
29.89
AGIO
-0.86%
34.50
XNCR
-2.54%
137.88
EHC
-2.98%

FAQ

What Is the Zymeworks (NASDAQ: ZYME) Share Price Today?

The Zymeworks stock price today is 25.84 USD.

What Stock Exchange Does Zymeworks (ZYME) Trade On?

Zymeworks is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for Zymeworks?

The stock symbol (also called a 'ticker') for Zymeworks is "ZYME."

What Is the Current Zymeworks Market Capitalisation?

As of today, Zymeworks (NASDAQ: ZYME) market cap is 1.78B USD.

What Is Zymeworks's (ZYME) Earnings Per Share (TTM)?

The Zymeworks EPS is currently 0.59 (Trailing Twelve Months).

When Is the Next Zymeworks Earnings Date?

Zymeworks's next earnings report will be released on 10/03/2027.

Is ZYME a Buy or Sell From a Technical Analyst Perspective?

Based on today's Zymeworks moving averages and other technical indicators, the daily buy/sell signal for ZYME stock is Strong Sell.

How Many Times Has Zymeworks Stock Split?

Zymeworks has split 0 times. (See the ZYME stock split history page for full effective split date and price information.)

How Many Employees Does Zymeworks Have?

Zymeworks has 279 employees, based on their latest Companies House report.

What is the current trading status of Zymeworks (NASDAQ: ZYME)?

As of 18/11/2026, Zymeworks (ZYME) is trading at a share price of 25.84 USD, with a previous close of 25.84 USD. The stock has fluctuated within a day range of 25.53 USD to 26.52 USD, while its 52-week range spans from 21.52 USD to 31.97 USD.

What Is Zymeworks (ZYME) Price Target According to Analysts?

The average 12-month price target for Zymeworks is 43.29 USD, with a high estimate of 60 USD and a low estimate of 35 USD. 14 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +67.51% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.